Edison Partners Exits RapidDeploy To Motorola Solutions
NASHVILLE, Tenn. & PRINCETON, N.J.--(BUSINESS WIRE)--Feb 24, 2025--
Growth equity firm Edison Partners announced today the exit of its investment in RapidDeploy to Motorola Solutions, the leading provider of cloud-native next-generation 911 mapping, mobile and analytics solutions for public safety agencies. Financial terms were not disclosed. Read Motorola Solutions' announcement here.
The Austin, TX-based company empowers public safety agencies across the United States with real-time intelligence to enhance emergency response and decision-making. RapidDeploy's cloud-native solutions integrate with an ecosystem of partners and applications, connecting millions of data points to deliver critical, life-saving information to public safety centers. Since 2016, RapidDeploy's technology has expanded to serve over one thousand six hundred 911 centers across 23 states, with 13 statewide contracts, democratizing public safety with cloud-native SaaS solutions.
'We are so pleased with the growth trajectory and strategic opportunity for RapidDeploy after making our initial $20M growth investment in 2023. We recognized that RapidDeploy had a unique ability to lead in a historically challenging space for new entrants,' said Chris Sugden, managing partner at Edison Partners. 'With the support of Edison's value creation resources, including Edison Director Network member Jo Kinsella, to advance the company's market leadership position, RapidDeploy CEO Steve Raucher and his team have taken the company to new heights and, with their state-of-the-art NextGen 911 technology, they've made our country's emergency response system stronger.'
RapidDeploy represents one of multiple portfolio companies that support Edison's investment thesis around digitizing critical infrastructure. Two additional recent investments supporting this theme include a $15M investment made in Seismos, an AI-driven technology firm using sound to make energy production safer, cleaner and more efficient, and a $43M growth investment in 120Water, a digital water solution helping the country's 50,000 state and local water utilities to protect public health through water safety, compliance, and wastewater monitoring programs. Further, in 2021, Edison invested in Recycle Track Systems which provides on-demand refuse removal to fully integrated waste management solutions, helping companies and municipalities easily track and optimize their services.
+1.917.287.3626
SOURCE: Edison Partners
Copyright Business Wire 2025.
PUB: 02/24/2025 07:11 AM/DISC: 02/24/2025 07:11 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Edison Issues Report on DUG Technology (DUG)
London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on DUG Technology (ASX: DUG). DUG Technology (DUG) provides seismic data processing services and software primarily to the oil and gas industry. As a small but innovative player in the field, the recent launch of elastic multi-parameter full waveform inversion (MP-FWI) technology gives the company the opportunity to gain market share despite the uncertain industry outlook. The recent Q325 update confirmed that order intake has returned to growth, supporting our forecasts for a recovery in revenue and profitability from FY26. In our view, this is not factored into the current share price. Uptake of solutions for immersion cooling and mobile high-performance computing (HPC) could provide further upside to our forecasts and valuation. Click here to read the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information, please contact Edison: enquiries@ Connect with Edison on: LinkedIn YouTube To view the source version of this press release, please visit
Yahoo
2 hours ago
- Yahoo
Edison Issues Report on DUG Technology (DUG)
London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on DUG Technology (ASX: DUG). DUG Technology (DUG) provides seismic data processing services and software primarily to the oil and gas industry. As a small but innovative player in the field, the recent launch of elastic multi-parameter full waveform inversion (MP-FWI) technology gives the company the opportunity to gain market share despite the uncertain industry outlook. The recent Q325 update confirmed that order intake has returned to growth, supporting our forecasts for a recovery in revenue and profitability from FY26. In our view, this is not factored into the current share price. Uptake of solutions for immersion cooling and mobile high-performance computing (HPC) could provide further upside to our forecasts and valuation. Click here to read the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information, please contact Edison: enquiries@ Connect with Edison on: LinkedIn YouTube To view the source version of this press release, please visit Sign in to access your portfolio
Business Upturn
10 hours ago
- Business Upturn
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS, United States: HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. This press release features multimedia. View the full release here: The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
